drugset / Trial / NCT04073953
Primaquine Enantiomers in G6PD Deficient Human Volunteers
Phase 1
Completed
18 enrolled
University of Mississippi, Oxford
University of Colorado, Denver · collab
Non-randomizedCrossoverOpen-labelBasic science
Summary
This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2023-09-01
- Completion
- 2023-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RPQ | Unknown | 15 mg | — |
| Subject | RPQ | Unknown | 22.5 mg | — |
| Subject | SPQ | Unknown | 15 mg | — |
| Subject | SPQ | Unknown | 22.5 mg | — |